The growth in the historic period can be attributed to increasing infertility prevalence, expansion of IVF clinics globally, rising awareness of hormonal infertility treatments, availability of recombinant hormone therapies, advancements in reproductive endocrinology.
The growth in the forecast period can be attributed to increasing maternal age trends, rising investments in fertility clinics, growing adoption of personalized reproductive medicine, expansion of fertility preservation services, increasing demand for advanced hormonal therapies. Major trends in the forecast period include increasing adoption of hormone-based fertility therapies, rising use of assisted reproductive technologies, growing demand for personalized fertility treatment protocols, expansion of combination hormone therapies, enhanced focus on controlled ovulation induction.
The increasing infertility rates are expected to drive the growth of the Luveris market in the coming years. Infertility rates refer to the percentage of couples or individuals who are unable to conceive after a certain period of trying, usually measured after a year of unprotected intercourse. The rise in infertility rates can be attributed to factors such as delayed childbearing, lifestyle choices, environmental pollutants, and underlying health conditions. Luveris (lutropin alfa) is used to treat infertility in women with low levels of luteinizing hormone (LH) by stimulating ovulation and encouraging the development of eggs in the ovaries. For example, in July 2023, the Human Fertilisation and Embryology Authority, a UK-based regulator of fertility treatment and research, reported that the number of patients undergoing in vitro fertilisation (IVF) at HFEA-licensed fertility centers rose to 52,400 in 2023, up from previous years. Additionally, donor insemination (DI) treatments resulted in around 820 births, a rise from previous years. Therefore, the increasing infertility rates are expected to drive the growth of the Luveris market.
The growing healthcare infrastructure is also expected to drive the growth of the Luveris market in the future. Healthcare infrastructure encompasses hospitals, clinics, medical equipment, healthcare workers, and other systems and resources needed to deliver healthcare services. The expansion of healthcare infrastructure is driven by increasing populations, aging demographics, advancements in healthcare technology, and the need for better access and quality of care. This expansion positively impacts Luveris by improving access to advanced fertility treatments and supporting the growth of specialized medical centers that utilize innovative therapies for infertility. For example, in May 2023, the UK government announced that it would invest more than $25.33 billion (£20 billion) in the New Hospital Programme, aiming to create 40 new hospitals in England by 2030, according to the Department of Health and Social Care. Therefore, the expansion of healthcare infrastructure is expected to drive the growth of the Luveris market.
A key trend in the Luveris market is the adoption of a strategic investment approach for the development and manufacturing of novel medicines. Strategic investments are made with the aim of achieving long-term business goals, such as gaining a competitive advantage, expanding market share, or enhancing operational capabilities. For example, in April 2024, Merck KGaA, a Germany-based science and technology company, invested $316 million (€300 million) in a new research facility at its international headquarters in Darmstadt, Germany. This advanced research center will focus on developing solutions for the manufacturing of antibodies, mRNA applications, and other biotechnological products within Merck’s Life Science business sector. The center will consolidate research on key technologies, including raw materials and processes for antibody production, recombinant proteins, and viral vectors. Additionally, it will support research in cell culture media, pharmaceutical formulation and purification aids, digital reference materials, and the further development of analytical chromatography. Research along the mRNA value chain will also be conducted at the new facility.
Major companies operating in the luveris market are Merck KGaA.
North America was the largest region in the luveris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the luveris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the luveris market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are influencing the luveris market by increasing costs of imported recombinant hormone ingredients, sterile injectable packaging materials, cold-chain storage systems, and precision manufacturing equipment. Fertility treatment providers in North America and Europe are most affected due to reliance on globally sourced biopharmaceutical inputs, while Asia-Pacific faces higher import costs for branded fertility drugs. These tariffs are contributing to higher treatment costs and affordability challenges for patients. At the same time, they are supporting regional biopharma manufacturing, local fill-and-finish operations, and supply chain localization for fertility therapeutics.
The luveris market research report is one of a series of new reports that provides luveris market statistics, including luveris industry global market size, regional shares, competitors with a luveris market share, detailed luveris market segments, market trends and opportunities, and any further data you may need to thrive in the luveris industry. This luveris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Luveris (lutropin alfa) is a synthetic form of luteinizing hormone used in fertility treatments for women with severe LH deficiency or those undergoing assisted reproductive technologies like in vitro fertilization (IVF). It works by mimicking natural LH to stimulate ovarian follicle development and ovulation, typically in combination with follicle-stimulating hormone (FSH). Administered via subcutaneous injection, Luveris plays a critical role in helping women achieve successful ovulation and pregnancy outcomes under the guidance of a healthcare provider.
The primary formulations of Luveris include injectable forms (intravenous) and pre-filled syringes. The injectable formulation is administered directly into the bloodstream through an intravenous (IV) injection. It is used to treat hypogonadotropic hypogonadism, induce ovulation, and assist with reproductive technologies. Luveris is available for both subcutaneous and intramuscular injection routes. It is used by various patient demographics, such as adult female patients, adult male patients, and couples undergoing fertility treatments. The medication is provided through hospitals, fertility clinics, specialty pharmacies, and home healthcare providers.
The luveris market consists of sales of follitropin alfa, menotropins, progesterone and follitropin beta. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to increasing maternal age trends, rising investments in fertility clinics, growing adoption of personalized reproductive medicine, expansion of fertility preservation services, increasing demand for advanced hormonal therapies. Major trends in the forecast period include increasing adoption of hormone-based fertility therapies, rising use of assisted reproductive technologies, growing demand for personalized fertility treatment protocols, expansion of combination hormone therapies, enhanced focus on controlled ovulation induction.
The increasing infertility rates are expected to drive the growth of the Luveris market in the coming years. Infertility rates refer to the percentage of couples or individuals who are unable to conceive after a certain period of trying, usually measured after a year of unprotected intercourse. The rise in infertility rates can be attributed to factors such as delayed childbearing, lifestyle choices, environmental pollutants, and underlying health conditions. Luveris (lutropin alfa) is used to treat infertility in women with low levels of luteinizing hormone (LH) by stimulating ovulation and encouraging the development of eggs in the ovaries. For example, in July 2023, the Human Fertilisation and Embryology Authority, a UK-based regulator of fertility treatment and research, reported that the number of patients undergoing in vitro fertilisation (IVF) at HFEA-licensed fertility centers rose to 52,400 in 2023, up from previous years. Additionally, donor insemination (DI) treatments resulted in around 820 births, a rise from previous years. Therefore, the increasing infertility rates are expected to drive the growth of the Luveris market.
The growing healthcare infrastructure is also expected to drive the growth of the Luveris market in the future. Healthcare infrastructure encompasses hospitals, clinics, medical equipment, healthcare workers, and other systems and resources needed to deliver healthcare services. The expansion of healthcare infrastructure is driven by increasing populations, aging demographics, advancements in healthcare technology, and the need for better access and quality of care. This expansion positively impacts Luveris by improving access to advanced fertility treatments and supporting the growth of specialized medical centers that utilize innovative therapies for infertility. For example, in May 2023, the UK government announced that it would invest more than $25.33 billion (£20 billion) in the New Hospital Programme, aiming to create 40 new hospitals in England by 2030, according to the Department of Health and Social Care. Therefore, the expansion of healthcare infrastructure is expected to drive the growth of the Luveris market.
A key trend in the Luveris market is the adoption of a strategic investment approach for the development and manufacturing of novel medicines. Strategic investments are made with the aim of achieving long-term business goals, such as gaining a competitive advantage, expanding market share, or enhancing operational capabilities. For example, in April 2024, Merck KGaA, a Germany-based science and technology company, invested $316 million (€300 million) in a new research facility at its international headquarters in Darmstadt, Germany. This advanced research center will focus on developing solutions for the manufacturing of antibodies, mRNA applications, and other biotechnological products within Merck’s Life Science business sector. The center will consolidate research on key technologies, including raw materials and processes for antibody production, recombinant proteins, and viral vectors. Additionally, it will support research in cell culture media, pharmaceutical formulation and purification aids, digital reference materials, and the further development of analytical chromatography. Research along the mRNA value chain will also be conducted at the new facility.
Major companies operating in the luveris market are Merck KGaA.
North America was the largest region in the luveris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the luveris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the luveris market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are influencing the luveris market by increasing costs of imported recombinant hormone ingredients, sterile injectable packaging materials, cold-chain storage systems, and precision manufacturing equipment. Fertility treatment providers in North America and Europe are most affected due to reliance on globally sourced biopharmaceutical inputs, while Asia-Pacific faces higher import costs for branded fertility drugs. These tariffs are contributing to higher treatment costs and affordability challenges for patients. At the same time, they are supporting regional biopharma manufacturing, local fill-and-finish operations, and supply chain localization for fertility therapeutics.
The luveris market research report is one of a series of new reports that provides luveris market statistics, including luveris industry global market size, regional shares, competitors with a luveris market share, detailed luveris market segments, market trends and opportunities, and any further data you may need to thrive in the luveris industry. This luveris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Luveris (lutropin alfa) is a synthetic form of luteinizing hormone used in fertility treatments for women with severe LH deficiency or those undergoing assisted reproductive technologies like in vitro fertilization (IVF). It works by mimicking natural LH to stimulate ovarian follicle development and ovulation, typically in combination with follicle-stimulating hormone (FSH). Administered via subcutaneous injection, Luveris plays a critical role in helping women achieve successful ovulation and pregnancy outcomes under the guidance of a healthcare provider.
The primary formulations of Luveris include injectable forms (intravenous) and pre-filled syringes. The injectable formulation is administered directly into the bloodstream through an intravenous (IV) injection. It is used to treat hypogonadotropic hypogonadism, induce ovulation, and assist with reproductive technologies. Luveris is available for both subcutaneous and intramuscular injection routes. It is used by various patient demographics, such as adult female patients, adult male patients, and couples undergoing fertility treatments. The medication is provided through hospitals, fertility clinics, specialty pharmacies, and home healthcare providers.
The luveris market consists of sales of follitropin alfa, menotropins, progesterone and follitropin beta. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Luveris Market Characteristics
3. Luveris Market Supply Chain Analysis
4. Global Luveris Market Trends and Strategies
5. Luveris Market Analysis of End Use Industries
7. Global Luveris Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Luveris Total Addressable Market (TAM) Analysis for the Market
9. Luveris Market Segmentation
10. Luveris Market Regional and Country Analysis
11. Asia-Pacific Luveris Market
12. China Luveris Market
13. India Luveris Market
14. Japan Luveris Market
15. Australia Luveris Market
16. South Korea Luveris Market
17. Western Europe Luveris Market
18. UK Luveris Market
19. Germany Luveris Market
20. France Luveris Market
21. Eastern Europe Luveris Market
22. North America Luveris Market
23. USA Luveris Market
24. Canada Luveris Market
25. South America Luveris Market
26. Middle East Luveris Market
27. Africa Luveris Market
29. Luveris Market Competitive Landscape and Company Profiles
32. Luveris Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Luveris Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses luveris market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for luveris? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The luveris market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Formulation: Injectable Formulation (Intravenous); Pre-Filled Syringes2) By Indication: Treatment Of Hypogonadotropic Hypogonadism; Ovulation Induction; Assisted Reproductive Technology
3) By Route of Administration: Subcutaneous Injection; Intramuscular Injection
4) By Patient Demographics: Adult Female Patients; Adult Male Patients; Couples Undergoing Fertility Treatments
5) By End User: Hospitals; Fertility Clinics; Specialty Pharmacies; Home Healthcare Providers
Companies Mentioned: Merck KGaA
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Luveris market report include:- Merck KGaA
